Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 18/20 | 0.75 |
| ▸ | CAPNS1 | P04632 | 4/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329295 | 0.86 | CAPN1 (1.00) | CAPN1CAPNS1CASP3 | |
| SCHEMBL7520605 | 0.82 | CAPN1 (0.65) | CAPN1CAPNS1CASP3 | |
| SCHEMBL7522342 | 0.82 | CAPN1 (0.65) | CAPN1CAPNS1CASP3 | |
| SCHEMBL8809577 | 0.81 | CAPN1 (0.71) | CAPN1CAPNS1CASP3 | |
| SCHEMBL8809563 | 0.81 | CAPN1 (0.71) | CAPN1CAPNS1CASP3 | |
| SCHEMBL5694021 | 0.80 | CAPN1 (0.78) | CAPN1CAPNS1 | |
| SCHEMBL4968796 | 0.79 | CAPN1 (1.00) | CAPN1CAPNS1 | |
| SCHEMBL8810647 | 0.79 | CAPN1 (0.67) | CAPN1CAPNS1CASP3 | |
| SCHEMBL8810659 | 0.79 | CAPN1 (0.67) | CAPN1CAPNS1CASP3 | |
| SCHEMBL4972742 | 0.78 | CAPN1 (1.00) | CAPN1CAPNS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIEQUES (S.C.R.A.S.) | 2004-09-16 | — | — | US | disclosed |
| US-6747024-B1 | INHIBITING CALPAIN AND/OR REACTIVE OXYGEN SPECIES IN WARM-BLOODED ANIMALS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-06-08 | — | — | US | disclosed |
| EP-1233962-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001032654-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885CAPNS1 3/4885CASP3 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.